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THE PROTHROMBIN GENE G20210A VARIANT IN AN 
UNSELECTED THROMBOEMBOLIC POPULATION. 
A belgian prospective clinical study. 
Ph. Hainaut1, J.L. Gala2.4, V. Lesage 1, E. Lavenne3, M.-A. Azerad3, F. Zechl, M. Heusterspreute2, 
M. Philippe2 , M. Moriau3 • 
SUMMARY 
The presence of the 2021 OA allele of the prothrombin 
gene has recently been shown to be a risk factor of venous 
thromboembolism, probably mediated through increased 
prothrombin levels. The aim of the study was to determi-
ne the frequency of the prothrombin 2021 OA allele in 193 
consecutive unselected patients with venous thromboem-
bolism and 100 healthy controls and to analyze the clini-
cal profile associa!ed wi~h this new inherited thrombophi-
lic factof. In agreement with previous reports, we found a 
frequency of 7.3% of heterozygous carriers of the 2021 OA 
allele among patients and 1% among controls. We con-
firm that plasma prothrombin levels are more elevated in 
the individuals bearing the prothrombin 20210A allele 
compared with those who do not. We did not find any re-
lationship between the presence of the prothrombin 
2021 OA allele and either a family history of thromboem-
bolism, the rate of recurrences or the age at disease onset. 
However, the co-inheritance in the same individual of both 
prothrombin 2021 OA allele and factor V Leiden was asso-
ciated with a significantly lower age at disease onset sug-
gesting a synergistic contribution of both abnormalities. 
INTRODUCTION 
Venous thromboembolism is a frequent disease 
with an annual incidence in the general population of 
approximately 1 per 1000. Risk factors involve both 
hereditary and acquired conditions. Mutations in ge-
nes coding for coagulation proteins play an increas-
ingly significant role. Until a few years ago, inheri-
ted deficiency of antithrombin III, protein C or pro-
tein S were the only single gene disorders related to 
the development of venous thrombosis but their pre-
valence remained low. Recently, the discovery of a 
single mutation of factor V responsible for activated 
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protein C resistance, also called factor V Leiden, em-
phasised the pivotal role of genetic analysis in un-
derstanding thrombophilic mechanisms (1 ,2). Factor 
V Leiden is encountered in more than 20% of throm-
boembolic patients, hence representing the most fre-
quent thrombophilia inherited factor (3,4 ). Despite 
this recent advance, many thrombotic events remai-
ned unexplained. At the end of 1996, another point 
mutation located at position 20210 in the 3' untnns-
lated region of the prothrombin gene and consisring 
in a G to A nucleotide transition was identified and 
associated with a 2.8 fold increased risk for venous 
thrombosis (5). It was reported in 6.2 % of unselec-
ted patients with a first episode of deep venous throm-
bosis and in 18% of patients with a familial history 
of venous thrombosis. The presence of the 2021 OA 
allele was also correlated with elevated plasma 
prothrombin levels permitting the hypothesis that the 
hypercoagulability conferred by the 2021 OA allele 
may be due to hyperactivity of the common coagula-
tion pathway (5). This observation prompted us to 
analyse a large cohort of patients presenting with well-
documented initial or recurring venous thromboem-
bolism. 
PATIENTS AND METHODS 
Patients with thrombosis and healthy control 
subjects 
The study population involved 193 unrelated pa-
tients treated in a single academic hospital between 
June 1993 and September 1997. One hundred volun-
teers (62 women and 38 men) with neither a personal 
nor a family history of thrombosis, recruited among 
the hospital employees and students were included as 
control subjects. The mean age of the control sub-
jects was 28 years (range: 20 to 64). Patients and con-
trols were of West European descent. 
Assays 
a) Blood sampling: 
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Blood was collected by clean venipuncture into 
tubes containing 0,106 M trisodium citrate for coa-
gulation assays and kalium-EDTA (1,6 mg EDTA/ml 
blood) for DNA processing. At blood sampling, none 
of the patients were receiving any medication that 
would interfere with the coagulation study. 
b) Coagulation assays. 
Platelet free plasma was obtained by centrifuga-
tion at 5000 g for 20 minutes at 4 oc and stored at 
- 20°C until required. Protein C and antithrombin 
levels were determined with functional methods using 
chromogenic substrates from Chromogenix® on a cen-
trifugal auto-analyser ACL200 (Instrumentation La-
boratory, Milan, Italy). Protein S was analysed by 
ELISA testing (free protein S). Lupus anticoagulant 
was evaluated by 3 screening tests (activated recalci-
fication time, activated partial thromboplastin time 
(AM), tissue thromboplastin inhibition test (TTI) 
(using Innovin Dade thromboplastin) and 2 confir-
ming methods involving plasmatic mixture and pla-
telet neutralisation. Factor II (prothrombin) assays 
were performed by a thromboplastin-based assay 
using factor II deficient plasma on a centrifugal auto-
analyser ACL200. 
c) DNA amplification and sequencing: 
DNA was extracted from peripheral blood leuko-
cytes using a QI Aamp Blood kit (Qiagen, Germany). 
For the screening of the Lei den mutation, the Arg 506-
Gln mutation of the factor V gene resulting from G-
A 1691 substitution was detected using digestion by 
the restriction enzyme Mnl-I of the products ampli-
fied by polymerase chain reaction, as described by 
Bertina (2). We adapted the detection of the factor II 
mutation from a previous report (5). A 204-bp frag-
ment from exon 14 and the 3'-untranslated region was 
amplified by PCR using two, rather than one, muta-






The antisense mutagenic primer was previously 
described by Poort et al (5). The design of the sense 
primer was based on the published human prothrom-
bin nucleotide sequence (6). The nucleotides under-
lined are not present in the normal sequence. The 
mutagenic primers introduced two Hind III restric-
tion sites in the mutated PCR products and only one 
in the wild type (WT) amplicons. After enzymatic 
digestion, three fragments (15, 23 and 166-bp) were 
yielded in mutated amplicons versus two (23 and 181-
bp) in WT. This modification of the original method 
was in order to control the quality of the enzymatic 
digestion and to avoid false-negative results in the 
case of unsuspected digestion failure. 
Diagnosis of thromboembolism 
Deep venous thrombosis was confirmed by duplex 
Doppler ultrasonography or venography. Pulmonary 
embolism was diagnosed by high probability lung 
scintigraphy according to Pioped criteria, angiogra-
phy or spiral computed tomography. 
Statistical Analysis 
Dichotomic values were compared using Fischer's 
exact test. Continuous values were analysed using the 
Wilcoxon test (p are two-sided). 
RESULTS 
Prothrombin 20210A allele prevalence 
Fourteen out of 193 patients (7 .3%) were hetero-
]:ygote carriers of the prothrombin gene 2021 OA alle-
le (mutant allele frequency 0.036) whereas this va-
riant was detected in only 1 out of 100 healthy con-
trols (1 %) (p < 0.05)(table 1). The 20210A allele was 
Table 1. Clinical profile of xatients with thromboembolic disease: comparison of overall population, patients with 
20210 allele and patients with the wild allele of the prothrombin gene. 
OVERALL factor II factor II statistical 
2021 OA allele wild allele significance 
HEALTHY CONTROLS 
number 100 I (1 %) 99 
male/female 38/62 011 38/61 
THROMBOEMBOLIC PATIENTS 
number 193 14 (7.3%) 179 
male/female patients 7511 I 8 4/10 711108 NS 
mean age (years) at I st thrombotic event 46.3 39.9 46.8 NS 
presenting thrombotic event 
proximal DVT 108 8 (57%) 100 (56%) 
distal DVT 57 3 (21%) 54 (30%) 
lung embolism 19 3 (21%) 16 (9%) 
varia 9 9 (5%) 
number of patients with positive family history 
of thromboembolic disease(%) 46/163 (28%) 5/13 (38%) 41/150 (27%) NS 
number of patients with recurrence of 
thromboembolic disease(%) 65/181 (36%) 5/14 (36%) 60/167 (36%) NS 
n of patients with predisposing risk factors I 09/193 (56%) 8/14 (57%) 101/179 (56%) NS 
frequency of lung embolism 71/161 (44%) 6/14 (43%) 65/147 (44%) NS 
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not identified in the homozygous state. 
Plasma prothrombin levels 
The relationship between plasma prothrombin le-
vels and the prothrombin genotype was analyzed in 
the first I 0 patients presenting the prothrombin 
2021 OA allele and in the first 40 patients with the 
wild type allele. The median prothrombin level was 
significantly increased in the first group: 1.16 U/ml 
compared to 1.04 U/ml in the latter (p ::;; 0.02, Wil-
coxon test). 
Clinical profile 
No correlation was found between heterozygous 
carriage of the 2021 OA allele and several parameters 
determining the clinical profile of thromboembolic 
disease (table 1): the distribution of thrombosis loca-
tion (proximal versus distal venous thrombosis), the 
frequency of associated pulmonary embolism, the 
proportion of patients with a family history of throm-
boembolism, the percentage of patients suffering from 
recurrences and the age at disease onset (table 2) were 
not affected by the presence of the prothrombin gene 
variant. Simil::trly, the risk factors commonly invol-
ved in venous thromboembolism, i.e. postoperative 
state, immobilisation, associated clotting disorders, 
were found with a similar frequency in both the nor-
mal and the variant prothrombin gene population. 
Association with other thrombophilia factors 
According to our previous study ( 4 ), factor V Lei-
den mutation was found in 42 out of 193 patients (21.8 
% ). Among the 14 patients with prothrombin 2021 OA 
allele, the association with protein S deficiency was 
encountered in 2 cases and with protein C deficiency 
in 1 case. Coexistence of both factor V Leiden and 
prothrombin 2021 OA allele was identified in 3 addi-
tional patients (3/193; 1.6% ). Interestingly, although 
the median age at first thromboembolism event was 
similar for patients with either factor V Leiden or fac-
tor II mutation alone compared to those with wild type 
Table 2. c?mbine~ th~ombophilic risk factors: compari-
son of Pl!hents With either no mutation, factor V Leiden 
mut~twn or factor II 20210A allele and individuals 
beanng ~oth ~ef~<;ts. The association of both defects 
results m a Sigmficantly lower age of disease onset 
compared to factor V Leiden alone or no mutation. 
patients median age (years) 
number at I st thrombotic event 
total 193 
no mutation 140 47"1 
factor V Leiden (alone) 39 46 (h) 
factor II 2021 OA allele _(alone) II 43 (I) 
fact. V Lei den and fact. II 
2021 OA allele (combined) 3 I 
zya)(b)(C) 
(a) . h p < 0.025, ( I p < 0.025; (i( NS 
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alleles (between 43 and 47 years), the figure was 
markedly lower (25 years) for the individuals bea-
ring both abnormalities. This difference was statisti-
cally significant (table 2). 
DISCUSSION 
The frequency of 7.3 %for heterozygous carriers 
of the prothrombin gene 2021 OA allele is in accor-
dance with the initially reported prevalence of 6.3 % 
among consecutive unselected thromboembolic pa-
tients (5). Similar observations were made by Cum-
ming et al. (7) reporting a prevalence of 5.5 %among 
patients with venous thrombosis and 1.2 % among 
healthy controls. Likewise, Hillarp et al. found a pre-
valence of 7.1 % among 99 Swedish unselected out-
patients with deep venous thrombosis and 1.8 % in 
the healthy control group (8). Moreover, we were able 
to confirm the relationship between prothrombin 
20210 AG genotype and significantly elevated plas-
ma prothrombin levels. However, no cut-off point was 
identified in order to discriminate reliably betw~en 
the prothrombin 2021 OA variant and the wild aHele 
on the basis of a plasma prothrombin level. 
Furthermore, the exact mechanism linking eleva-
ted plasma prothrombin levels to the risk of venous 
thromboembolism remains speculative. 
A more in-depth analysis allowed assessment of 
the clinical profile of patients bearing the 2021 OA 
prothrombin variant. Firstly, the frequency of 
prothrombin 2021 OA variant among our patients with 
and without a familial history of thromboembolism 
was 10.8 % (5/46 patients) and 6.8% (81117 patients), 
respectively, this difference was not significant. The 
frequency of prothrombin variant carriers was repor-
ted by Poort et al. to be as high as 18% among pa-
tients with a personal and a family history of throm-
boembolism but the figure may have been influenced 
by selection bias, as suggested by the authors. Se-
condly, the frequency of factor V Lei den was similar 
among the patients bearing the 20210 AG genotype 
(3114 patients, 21 %) and the patients bearing the wild 
prothrombin allele (36/179 patients, 20%). The rate 
of 40% found by Poort et al. can be explained by the 
smaller size of their cohort and the selection of pa-
tients with a familial clustering of venous thromboem-
bolism. Our data are in agreement with the prevalen-
ce reported elsewhere (9). Thirdly, we found that the 
frequency of associated risk factors, i.e. postoperati-
ve state, immobilisation or other clotting defects, was 
similar among the carriers of 20210 AG variant and 
the patients with the wild type genotype. The same 
applied to the location of the thrombotic process (dis-
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tal versus proximal) and the frequency of associated 
pulmonary embolism that were identical, whether the 
prothrombin mutation was present or not. Contrary 
to observations regarding factor V Lei den ( 4, 1 0), the 
relapse rate was not higher among carriers of the 
prothrombin 2021 OA allele. Moreover, the mean age 
at disease onset was identical in normal and prothrom-
bin gene heterozygous patients. This observation con-
trasts with the analysis of Hillarp et al. who did not 
find any carriers of the 20210A allele among patients 
less than 62 years (8). This discrepancy has already 
been underlined by Rosendaal et al. (11). 
Overall, the data suggest that factor II mutation is 
probably a moderate thrombophilic factor. The stri-
kingly lower median age at the first thrombotic event 
in patients with co-inheritance of both prothrombin 
20210A allele and factor V Leiden suggests a syner-
gistic contribution of both factors. Although this lat-
ter finding relied on a limited number of patients and 
required further confirmation, it was in agreement 
with the very recent observations of Makris et al. who 
demonstrated that among patients with either factor 
V Leiden, protein S deficiency, protein C deficiency 
or antithrombin deficiency, the simultaneous carria-
ge of prothrombin 2021 OA allele was responsible for 
an increased number of venous thromboembolic epi-
sodes in comparison with the wild prothrombin allele 
carriers (12). This synergistic action could favour the 
hypothesis that a higher concentration of prothrom-
bin linked to 2021 OA allele results in an increased 
thrombin generation which appears to be also the re-
sult of either APC resistance or deficiencies of pro-
tein C and S (13). 
While the association of prothrombin 2021 OA va-
riant with venous thromboembolism has been esta-
blished beyond doubt, its potential contribution to 
arterial disease was suggested by several studies 
(14,15). These preliminary findings, however, need 
to be confirmed before assessing the role of prothom-
bin variant in arterial disease. 
In conclusion, the prothrombin 20210 A allele 
appears to be a moderate but relatively common 
thrombophilic factor. In our series of patients, the fre-
quency of thrombosis recurrence, age at onset and the 
prevalence of a family history were not influenced 
by the carriage of prothrombin 20210 A allele. Inte-
restingly, the co-inheritance of prothrombin 20210 AG 
variant and factor V Leiden in the same individual, 
although rare, may act synergistically as suggested 
by a very low age at disease onset. 
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RESUME 
L'existence de l'allele 20210A du gene de Ia prothrom-
bine a ete recemment identifie comme un facteur de ris-
que de Ia maladie thromboembolique veineuse; son action 
est probabl'-.o"llent mediee par l'augmentation du taux plas-
matique de prothrombine. Notre but a ete d'une part, de 
determiner Ia frequence de l'allele 20210A de Ia prothrom-
bine parmi 193 patients consecutifs traites pour une mala-
die thromboembolique et parmi 100 volontaires sains et 
d'autre part d'analyser le profil clinique associe a ce nou-
veau facteur de thrombophilie. En concordance avec 
d'autres observations, nous mettons en evidence une fre-
quence de 7,3 % de porteurs heterozygotes de l'allele 
20210A parmi les patients et de 1% parmi les controles. 
Nous confirmons que les taux plasmatiques de prothrom-
bine sont statistiquement plus eleves chez les individus 
porteurs de l'allele mute par rapport aux autres. 
Nous ne mettons pas de relation en evidence entre la 
presence de l'allele 20210A et une histoire familiale de 
maladie thromboembolique, la frequence des recidives ou 
!'age de debut de la maladie thromboembolique. Cepen-
dant, la presence chez le meme individu de la mutation de 
Leiden (facteur V) et de l'allele 20210A de la prothrombi-
ne est associee a un debut significativement plus precoce 
de !'affection suggerant !'intervention synergique de ces 
deux facteurs de thrombophilie. 
SAMENVATTING 
Het bestaan van het allel 20210A van het protrombine 
gen werd recent gei:dentificeerd als een risikofaktor van 
veneuze tromboembolie. Zijn werking is waarschijnlijk 
gemedieerd door een verhoging van het protrombine plas-
magehalte. Ons doel was enerzijds de frekwentie van het 
protrombine allel 20210A te bepalen bij 193 opeenvol-
gende patienten behandeld voor veneuze tromboembolie 
en bij 100 gezonde vrijwilligers, en anderzijds het bijko-
mend klinisch profiel te analyseren in verband met deze 
nieuwe trombose bevorderende faktor. In akkoord met 
vroegere bevindingen, vonden wij een frekwentie van 7,3% 
heterozygote dragers van het allel 20210A bij de patien-
ten, en 1% bij de controles. Wij bevestigen dat het plas-
magehalte aan protrombine statistisch hoger is bij dragers 
van het gemuteerde allel dan bij controles. Wij kunnen 
geen verband aantonen tussen de aanwezigheid van het 
allel20210A en een familiale voorgeschiedenis van trom-
boembolische ziekte, de frekwentie van recidieven of de 
leeftijd bij het begin van de aandoening. Nochtans, de 
aanwezigheid bij eenzelfde persoon van de mutatie van 
Leiden (faktor V) en het allel 20210A van protrombine is 
geassocieerd aan een duidelijk vroegtijdiger begin van de 
aandoening, veronderstellend een synergische tussenkomst 
van deze twee trombofilie risikofaktoren. 
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